Business Overview: Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)

---

Executive Summary

Insight Molecular Diagnostics Inc. (iMDx), formerly known as Oncocyte Corporation, is an early-commercial diagnostics technology company whose stated mission is to "expand access to novel molecular diagnostic testing," starting with transplant organ rejection monitoring. Its flagship approach quantifies donor-derived cell-free DNA (dd-cfDNA), a biomarker that rises in a patient's blood when a transplanted organ is being rejected.

iMDx operates a CLIA-certified lab in Franklin, Tennessee and has partnered with Bio-Rad to run its assays on Bio-Rad's digital PCR platform. The company matters less for its current scale — it is still early-commercial and out-of-network with most payers — and more because it is targeting an estimated $2 billion kitted transplant-testing market dominated by a small number of entrenched send-out lab competitors.

---

1. Core Business Model & How They Work

[ dd-cfDNA Biomarker Science ] ➡️ [ Lab-Developed Test (GraftAssureCore) ] ➡️ [ Kitted RUO/IVD Products (GraftAssureIQ/Dx) ] ➡️ [ Hospital & Transplant Center Adoption ] ➡️ [ Payer Reimbursement ]

Key Operational Drivers

1. In-House Kitted Testing Model: Unlike competitors that require samples to be sent to a centralized reference lab, iMDx's long-term strategy is to sell test kits that hospitals and transplant centers can run themselves — a faster, more decentralized model.
2. Bio-Rad Partnership: A global partnership puts iMDx's assays on Bio-Rad's digital PCR instruments, giving it access to an installed base of lab equipment without building its own hardware platform.
3. Reimbursement-Driven Ramp: CMS raised the GraftAssureCore reimbursement rate to $2,753 per result in May 2025, an important step toward commercial viability, though the company remains out-of-network with all commercial payers, with private payer coverage typically taking 12-24 months to establish.
4. IP from the Chronix Acquisition: Nine patent families acquired with Chronix underpin its position, supplemented by a new U.S. patent (awarded July 2025) covering a colorectal cancer detection method — a secondary, non-core application of the same core technology.

---

2. Business Segments

iMDx operates as a single diagnostics business, organized around products rather than reporting segments:

• Transplant Diagnostics (Primary Focus): GraftAssureCore (reimbursed LDT), GraftAssureIQ (research-use-only kit, first units sold May 2025), and GraftAssureDx (kitted clinical IVD; FDA data package submitted March 2026).
• Oncology (Secondary, Non-Core): DetermaIO and DetermaCNI, legacy Oncocyte oncology assets the company has stated it does not plan to commercialize within 12 months.
• Laboratory Services: Assay development and clinical testing services for life sciences and biotech customers.

---

3. Product Portfolio

---

4. Competitive Landscape

iMDx is a clear challenger, not a leader, in transplant diagnostics. Established competitors — CareDx, Natera, Transplant Genomics, Omixon, and Devyser — have existing customer relationships, broader payer coverage, and years of clinical adoption. iMDx's stated differentiation is digital PCR sample economics that are more favorable at low testing volumes, faster turnaround, and absolute (rather than relative) quantification. The company explicitly describes itself in its own 10-K as early-stage with limited resources relative to these competitors — an unusually candid admission of a weak current competitive position that it hopes its kitted, decentralized model will offset over time.

---

5. Strategic Strengths & Risks

Strengths

• Differentiated Technical Approach: Absolute quantification via digital PCR, versus competitors' relative quantification methods, is a genuine scientific differentiator the company can point to.
• Large Addressable Market: A ~$2 billion estimated market for kitted transplant rejection testing offers substantial room to grow from a small current base.
• Bio-Rad Partnership: Reduces the capital burden of building proprietary hardware and gives access to an existing instrument installed base.
• Reimbursement Progress: The 2025 CMS rate increase to $2,753/result is a concrete, favorable step for the core LDT product.

Risks

• Entrenched, Better-Resourced Competitors: CareDx and Natera in particular have significant head starts in customer relationships and payer coverage.
• Payer Coverage Gap: Being out-of-network with all commercial payers, with a 12-24 month typical timeline to establish coverage, is a material near-term revenue constraint.
• Narrow Current Commercial Base: GraftAssureCore is the only currently reimbursed product; GraftAssureDx (the kitted IVD meant to be the real scale driver) is still pending FDA review.
• Elevated Cash Burn: Net losses of $50.2M (2025) and $60.7M (2024), alongside rising R&D spend ($15.9M in 2025 vs. $9.8M in 2024), underscore the capital intensity of the commercial ramp.

---

6. Financial Overview

---

7. Summary Conclusion

iMDx is a small, early-commercial challenger pursuing a genuinely differentiated technical and commercial strategy — decentralized, kitted dd-cfDNA testing — in a transplant diagnostics market currently dominated by centralized, send-out lab competitors like CareDx and Natera. The company's own candor about being resource-constrained relative to those competitors is a fair read of its position: its long-term value depends almost entirely on successfully commercializing GraftAssureDx and converting the favorable 2025 CMS reimbursement decision into broader private payer coverage before its cash runway and competitive window close.